An Optimized Full-Length FLT3/CD3 Bispecific Antibody Demonstrates Potent Anti-leukemia Activity and Reversible Hematological Toxicity
Authors:
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier in Molecular Therapy
- Vol. 28 (3) , 889-900
Abstract
No abstract availableKeywords
Funding Information
- Pfizer, Inc.
This publication has 50 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging AntibodyScience, 2008
- Serial killing of tumor cells by cytotoxic T cells redirected with a CD19‐/CD3‐bispecific single‐chain antibody constructInternational Journal of Cancer, 2005
- FLT3 mutations in childhood acute lymphoblastic leukemiaBlood, 2004
- FLT3 ligand causes autocrine signaling in acute myeloid leukemia cellsBlood, 2004
- The role of FLT3 in haematopoietic malignanciesNature Reviews Cancer, 2003
- FLT3 mutations in acute myeloid leukemia cell linesLeukemia, 2003
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Interleukin 2 Leads to Dose-Dependent Expression of the Alpha Chain of the IL-2 Receptor on CD25-Negative T Lymphocytes in the Absence of Exogenous Antigenic StimulationClinical Immunology, 2000
- FLT3/FLK‐2 (STK‐1) Ligand Does Not Stimulate Human Megakaryopoiesis In VitroStem Cells, 1996